BioWatch News is a globally-focused biotech stock analysis company with a long-term market view and a passion for the biotech industry that goes far beyond investment news.

We prove this in each and every one of our publications by taking our readers on a deep-dive into the science, technology, and people behind the companies shaping today’s biotech headlines in both the private and public sectors.

Why do we do this? Simple. We know it takes more than a great concept and a good platform to make a winning company; and we know that in order for our readers to make informed decisions, we need to enable them through a greater understanding of the “why or why not” in the science behind their investment choices.

In the immortal words of Albert Einstein, “If you can't explain it simply, you don't understand it well enough." What truly makes us unique is our commitment to plain English coverage so even if you are new to biotech investing, you can be assured our publications will be easy to understand.

To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates? Want to purchase this issue?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates? Want to purchase this issue?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
To access this article, you can log in or subscribe.
Want exclusive access to our latest market research and company updates?
Subscribe
Already a subscriber?
BioMarin Pharmaceutical ( Nasdaq:BMRN )
Capricor Therapeutics, Inc ( OTC:CAPR )
Cardio3 BioSciences ( OTC:CIBSF )
Conatus Pharmaceuticals ( Nasdaq:CNAT )
Corcept Therapeutics ( Nasdaq:CORT )
Esperion Therapeutics ( Nasdaq:ESPR )
Evoke Pharma ( Nasdaq:EVOK )
Kindred Biosciences ( Nasdaq:KIN )
Medivation ( Nasdaq:MDVN )
Raptor Pharmaceutical ( Nasdaq:RPTP )
RepliCel Life Sciences ( TSXV:RP )
Seattle Genetics ( Nasdaq:SGEN )
Sorrento Therapeutics ( Nasdaq:SRNE )

Ambit Bioscience can be characterized as “the kinase enzyme inhibitor company”. It has generated about 8,000 inhibitors of enzymes that regulate key cellular processes like growth, proliferation, differentiation, and survival. Its lead product, Quizartinib, is finishing a successful program of Phase I and Phase II trials. A Phase III trial launch in relapsed / refractory acute myeloid leukemia (RR AML) is planned for early 2014.

AMBI has two other inhibitors in early development. AC410 has completed a Phase I trial in healthy volunteers; it is aimed at autoimmune and allergic diseases. AC708 is very potent and very precise but must undergo further testing before human trials. Management is currently focusing most of the resources on Quizartinib rather than advancing other programs.

  • Alan Leong
Corinne Jordan

Corinne Jordan

Chief Executive Officer

Corinne Jordan is an entrepreneurial-minded technical and marketing business collaborator with a particular passion for art and design. She has 16 years of demonstrated success delivering solution-based strategies in the public and private sectors. Corinne has also spent the last decade coaching and mentoring start-ups and preexisting companies ranging from software development to developing public personas.

To Corinne, creative brainstorming is the wellspring of solution and invention. This attitude allowed Corinne the honor of working on several disruptive technologies, which are commonplace today.

Corinne has also led several projects in the creation phase for clients such as: Heineken; Stan Kramien, the magician; the U.S. Poker Tour; A-America; Krames-Staywell; NAPMW; and Source Rates among many others.

Lastly, Corinne held board-level and C-level positions within several companies and wrote for numerous finance publications and journals in the areas of business development, marketing, branding, social media and regulation.

In her role at BioWatch News, Corinne will combine her lifelong passion for the sciences with her extensive design training, and her background in business development, to continually push the envelope on the future vision of our publication and the value we offer to our subscribers.

Alan Leong

Alan Leong

Alan Leong has had a professional passion for the life sciences industry for almost 20 years. He enjoys watching the commercial life science and engineering industries bring hope, health, and life our world. He started as an industry and technology analyst for a life science consultancy and segued into other similar positions throughout his career.

In his role at BioWatch, Alan will take a venture analyst’s approach to examining the companies we choose to highlight. He favors young companies that have winning business models. This has been reflected in his inclination towards companies that are developing drugs for orphan indications.  He also delights in learning about the commercial science behind promising game changers.

Prior to BioWatch News, Alan was the co-founder and Director of Research for Biotech Stock Research (BSR): a boutique service for life science investors. Over its 12 years of operations, he published over 1,500 pages for BSR and wrote over 45 main feature stories plus numerous alerts, company updates, and annual reviews.

Currently Alan is also a professor for the UW Foster School of Business. Over the years, Alan has taught entrepreneurship, technology forecasting, and venture investing. He is also the recipient of multiple teaching awards and was the founding director for the Center for Student Entrepreneurship at UW Bothell.

Alan has taught, mentored, and advised 100 start-ups and scale-ups in an array of industries from consumer retail to biotechnology. He also enjoys holding events in support of Dragon Curve—one of the largest entrepreneur communities in the State of Washington.

Omar Valdes

Omar Valdes

Art Leprechaun

Omar has had an extensive career that spans several decades and stretches coast-to-coast across the U.S. Dubbed the “Art Leprechan,” Omar creates happiness and entertainment wherever he goes with his illustrations.

It is almost a sure guarantee that you have seen some of Omar’s work prior to the covers he designed for BioWatch News; as he created several famous pieces for companies like Snapple, Pepsi, and the logo for “Men on Film” for the TV show, In Living Color.

Omar has also created commercial art for greats such as George Schlatter, Ralph Lauren, David Womach and many other famous faces in entertainment.

If you ask Omar his “Andy Warhol 15 minutes of fame” he would most-likely credit it to his coverage in the New York Times for creating specially painted game balls for defining moments in NBA and NFL history, or the game jerseys for the Devils.